Blood donation process depicting the donor's arm with a needle while a healthcare provider is present during a safe, voluntary blood collection procedure
The smallest patients in India's hospitals have the most specific blood needs — and the fewest options when those needs are not met.
A premature baby needing an exchange transfusion for severe jaundice cannot wait for the blood bank to source a compatible unit tomorrow. A five-year-old with severe thalassemia on a monthly transfusion schedule needs blood every time, on time, with minimal variation. A child with acute leukaemia on induction chemotherapy may need red blood cells and platelets multiple times in a single week.
Paediatric blood transfusion in India is not a subset of the general blood supply challenge. It is a distinct discipline with specific requirements, higher safety standards, and consequences of failure that fall on families with the least ability to navigate the system.
India's national blood demand study attributed approximately 1.2 million units to the paediatric specialty — about 8.5% of total national blood demand. The primary drivers of paediatric blood demand are:
Each of these demand categories has distinct blood product requirements, and failing to meet them has consequences that range from developmental harm to death.
Newborns receiving blood transfusions represent the most specialised niche in transfusion medicine. Their blood volumes are tiny — a newborn weighs 2–4 kg and has only 80–100 ml of blood per kg — meaning transfusions are measured in small fractions of a unit. Errors in volume, temperature, or compatibility are dangerous in ways that adult transfusion errors are not.
Exchange transfusion in newborns — where a large proportion of the baby's blood is replaced — is performed primarily for:
1. Haemolytic disease of the newborn (HDN): When an Rh-negative mother carries an Rh-positive baby (or in ABO incompatibility), maternal antibodies cross the placenta and attack the baby's red blood cells. Severe HDN can cause life-threatening anaemia, high bilirubin levels causing brain damage, and hydrops fetalis (severe fluid accumulation). Exchange transfusion replaces the sensitised blood with compatible blood.
2. Severe neonatal jaundice (hyperbilirubinaemia): When bilirubin — a breakdown product of red blood cells — accumulates faster than the newborn's immature liver can process it, levels can reach toxic concentrations that cause permanent brain damage (kernicterus). Phototherapy treats mild-moderate cases; severe cases may require exchange transfusion.
The blood used for neonatal exchange transfusion must meet strict specifications:
Finding blood that meets all these specifications simultaneously — particularly in smaller hospitals — is genuinely challenging. Blood banks with advanced capabilities (leukoreduction, irradiation) are concentrated in major city hospitals; neonatal referral units in smaller cities often have to source from these centres.
Thalassemia major affects the largest portion of India's paediatric blood demand — and it represents one of the most demanding continuous supply challenges in the system.
A child with thalassemia major begins needing blood transfusions in the first six months of life, as their bone marrow's abnormal haemoglobin production becomes apparent. Without transfusions, the child develops severe anaemia, skeletal deformities (as the bone marrow expands to compensate for red cell loss), growth failure, and organ damage.
With regular transfusions — every 3–4 weeks — these children develop normally. They attend school. They have childhoods.
India has an estimated 10,000–12,000 children born with thalassemia major each year — a new cohort added to the existing 100,000 patients already dependent on the transfusion system. Each child requires approximately 15–20 units of blood per year. The cumulative demand from India's thalassemia major population alone approaches 1.5–2 million units annually.
These are not sick children being kept comfortable for a few months. These are children expected to live decades — and each of those decades requires continuous blood supply from the voluntary donor system.
Acute leukaemia — particularly Acute Lymphoblastic Leukaemia (ALL) and Acute Myeloid Leukaemia (AML) — is the most common form of childhood cancer. In leukaemia, abnormal white blood cells multiply uncontrollably in the bone marrow, crowding out normal blood production.
The disease itself causes anaemia and thrombocytopenia (low platelets). The chemotherapy used to treat it makes both worse. During induction chemotherapy — the most intensive phase, typically 4–8 weeks — children with AML or ALL may require:
A child going through leukaemia induction at a hospital like Tata Memorial in Mumbai, AIIMS Delhi, or a regional cancer centre may require 20–30 units of blood components in a single treatment phase — and this is before maintenance chemotherapy, which continues for 1–3 years.
Paediatric leukaemia treatment is one of the most blood-intensive programmes in oncology — and the demand it places on blood banks near major paediatric cancer centres is continuous and high.
Nutritional anaemia — primarily iron deficiency — is among the most prevalent childhood health problems in India. The National Family Health Survey has consistently shown high rates of anaemia in children under 5, with rates in some states exceeding 70%.
When nutritional anaemia is severe — haemoglobin below 5–7 g/dL — transfusion may be necessary in addition to iron supplementation, particularly if the child has signs of cardiac decompensation (heart working too hard to compensate for lack of oxygen delivery).
The burden of severe nutritional anaemia on blood banks is less visible than thalassemia or leukaemia — because most children with severe anaemia present at district and community hospitals rather than tertiary centres, and because many go untreated rather than receiving transfusions. But the demand exists, and where blood is available, it saves children from the long-term developmental consequences of chronic severe anaemia.
Most voluntary blood donors are not directly aware that their donation may go to a child. The blood banking system allocates blood based on clinical need and compatibility — not donor preference. But knowing that paediatric patients — particularly neonates and children with thalassemia or leukaemia — are among the most specific and vulnerable consumers of India's blood supply changes the meaning of each donation.
1. If you are O-negative: A significant portion of neonatal blood demand goes specifically to O-negative donors. Your blood may go directly to exchange transfusions in newborns with haemolytic disease.
2. If you are a regular platelet donor: Children on chemotherapy receive platelet transfusions regularly. A fortnightly apheresis donation sustains patients through the most dangerous phases of leukaemia treatment.
3. If you donate every 90–120 days: The cumulative supply your donations contribute includes the red blood cell component used for thalassemia children's monthly transfusions.
Register on TheBloodApp. Donate regularly. Children with thalassemia, newborns with jaundice, and children battling leukaemia are among the most vulnerable patients in India's blood system. Your donation reaches them. To find blood banks and donation camps near you across India, call the number listed in the app.
Sources: PLOS ONE — National Blood Demand Study India | NBTC India | WHO India Blood Safety 2024 | PMC — Thalassemia India Blood Transfusion Challenges | ICMR — Thalassemia in India | eRaktKosh MoHFW — Blood Component Guide | FOGSI — Blood Transfusion Neonates
Stay informed, stay inspired — your go-to source for everything about blood donation and impact.
India's paediatric blood demand is 1.2 million units per year. Children with leukaemia, severe anaemia, thalassemia, and neonatal jaundice all depend on donated blood. Here's what every donor should know.
Over 800 million Indians live in rural areas where blood access is critically limited. Here's what the data shows about rural blood donation barriers — and how apps like TheBloodApp are helping.
Surgeries account for 27.9% of India's annual blood demand — 4.1 million units. From cardiac bypass to orthopaedic trauma, here's how donated blood makes surgery possible.
Be a part of the change — donate safely, stay connected, and help someone in need. Download the app today.
Available on
